Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form

Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7-10, 2015, San Diego, CA

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Parren, P.W. H. I.
  • Burton, Dennis
  • Bradbury, A.
  • Huston, J. S.
  • Carter, P. J.
  • Veldman, T.
  • Chester, K. A.
  • Larrick, J. W.
  • Alfenito, M. R.
  • Scott, J. K.
  • Weiner, L. M.
  • Adams, G. P.
  • Reichert, J. M.

publication date

  • November 2015

journal

  • MAbs  Journal

abstract

  • Antibody Engineering & Therapeutics, the annual meeting of The Antibody Society, will be held in San Diego, CA in early December 2015. In this meeting preview, the chairs provide their thoughts on the importance of their session topics, which include antibody effector functions, reproducibility of research and diagnostic antibodies, new developments in antibody-drug conjugates (ADCs), preclinical and clinical ADC data, new technologies and applications for bispecific antibodies, antibody therapeutics for non-cancer and orphan indications, antibodies to harness the cellular immune system, overcoming resistance to clinical immunotherapy, and building comprehensive IGVH-gene repertoires through discovering, confirming and cataloging new germline IGVH genes. The Antibody Society's special session will focus on "Antibodies to watch" in 2016, which are a subset of the nearly 50 antibodies currently in Phase 3 clinical studies. Featuring over 100 speakers in total, the meeting will commence with keynote presentations by Erica Ollmann Saphire (The Scripps Research Institute), Wayne A. Marasco (Dana-Farber Cancer Institute/Harvard Medical School), Joe W. Gray (Oregon Health & Science University), and Anna M. Wu (University of California Los Angeles), and it will conclude with workshops on the promise and challenges of using next-generation sequencing for antibody discovery and engineering from synthetic and in vivo libraries and on computational antibody design.

subject areas

  • Antibodies, Bispecific
  • Antibodies, Monoclonal
  • Drug Discovery
  • Humans
  • Immunoconjugates
  • Immunoglobulin Fc Fragments
  • Immunotherapy
  • Protein Engineering
  • Translational Medical Research
scroll to property group menus

Research

keywords

  • antibody engineering
  • antibody repertoire
  • antibody-drug conjugates
  • bispecific antibodies
  • computational design
  • next-generation sequencing
  • reproducibility
scroll to property group menus

Identity

PubMed Central ID

  • PMC4966390

International Standard Serial Number (ISSN)

  • 1942-0862

Digital Object Identifier (DOI)

  • 10.1080/19420862.2015.1089707

PubMed ID

  • 26421752
scroll to property group menus

Additional Document Info

start page

  • 981

end page

  • 988

volume

  • 7

issue

  • 6

©2021 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support